The impact of inflammation on the extinction of pain-related fear
- Conditions
- Healthy subjects
- Registration Number
- DRKS00016706
- Lead Sponsor
- niversitätsklinikum Essen,Institut für Medizinische Psychologie und Verhaltensimmunbiologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 95
Healthy subjects, body mass index (BMI) >19 and <30, non-smokers
Acute oder chronic inflammation, infectious diseases, gastrointestinal diseases, hepatic and liver diseases, cardiovascular diseases, hematological disorders, respiratory diseases, diabetes and other metabolic disorders, adipositas, psychiatric disorders, addiction. Regular drug intake, pain medication, participation in clinical pharmacoligical studies.
Additional exclusion criteria for women: hormonal contraception, pregnancy, nursing
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of perceived CS and US unpleasantness, perceived CS-US contingency, and US intensities during acquisition, extinction and reinstatement using visual analogue scales; assessment the fear response by electrodermal activity (skin conductance); measurement of brain neural activity (BOLD response) during aquisition, extinction and reinstatement using functional MRI<br><br>
- Secondary Outcome Measures
Name Time Method Quantification of pro- and anti-inflammatory cytokines as well as cortisol und norepinephrine in plasma/serum before (baseline) as well as 1, 2, 3, 4, 6 and 24 hours after administration of endotoxin/placebo; assessment of mood, sleepiness, and sickness behavior before (baseline) as well as 1, 2, 3, 4, 6 and 24 hours after administration of endotoxin/placebo using standardized questionnaires: State Trait Anxiety Inventory (STAI), State Trait Anxiety Depression Inventory (STADI), Profile of Mood States (POMS), Stanford Sleepiness Scale (SSS), Sickness Score; brain structure and connectivity